Allurion: Allurion Technologies launches AI weight loss program complementing GLP-1 agonist prescription service

Allurion Technologies has launched an AI-based weight loss and monitoring program, AllurionMeds, in the US. The program works in tandem with its GLP-1 drug prescription services. It addresses the most common GLP-1 treatment concerns, including weight regain, while offering virtual access to dieticians through a companion app. Program patients will receive support from a virtual guide, Coach Iris, and be prescribed GLP-1 drugs sourced from a US FDA-registered 503b facility. Allurion highlights that every batch has been tested for sterility and potency, among other things, before release.